natgillin/translations-raw huggingface dataset:
In a clinical study where ritonavir 100 mg capsules bid were coadministered with 50 µg intranasal fluticasone propionate (4 times daily) for 7 days in healthy subjects, the fluticasone propionate plasma levels increased significantly, whereas the intrinsic cortisol levels decreased by approximately 86% (90% confidence interval 82-89%).
U kliničkom ispitivanju na zdravim dobrovoljcima u kojem su ritonavir 100 mg kapsule bile primjenjivane s 50 µg intranazalnog flutikazonpropionata (4 puta dnevno) u trajanju 7 dana, vrijednosti flutikazonpropionata u plazmi su se značajno povisile, dok su se vrijednosti endogenog kortizola smanjile za oko 86% (90% interval pouzdanosti 82-89%).
This leaflet was last approved in {MM/YYYY} Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Ova uputa je zadnji puta revidirana u {MM/GGGG} Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove: http://www.ema.europa.eu.
In a study performed in antiretroviral naïve adult patients, tipranavir 500 mg with ritonavir 200 mg twice daily, as compared to lopinavir/ritonavir, was associated with an excess in the occurrence of significant (grade 3 and 4) transaminase elevations without any advantage in terms of efficacy (trend towards a lower efficacy).
U kliničkom ispitivanju s prethodno neliječenim odraslim bolesnicima tipranavir 500 mg s ritonavirom 200 mg dvaput dnevno, u usporedbi s lopinavir/ritonavirom, bio je povezan s prekomjernim značajnim (stupanj 3 i 4) povišenjem transaminaza, bez ikakvih prednosti u smislu djelotvornosti (tendencija k manjoj djelotvornosti).
Reverse genetic experiments showed that the presence of 6 mutations in the protease (I13V, V32I, L33F, K45I, V82L, I84V) was required to confer > 10-fold resistance to tipranavir while the full 10-mutation genotype conferred 69-fold resistance to tipranavir.
Reverzni genetski eksperimenti pokazuju da je potrebno prisustvo 6 mutacija u proteazi (I13V, V32I, L33F, K45I, V82L, I84V) za postizanje > 10-struke rezistencije na tipranavir, dok je potpuni 10mutacijski genotip imao 69-struku rezistenciju na tipranavir.
Taking Aptivus, with atazanavir, may cause the blood levels of Aptivus and ritonavir to increase a lot.
Uzimanje Aptivusa s atazanavirom može izazvati veliko povišenje razine Aptivusa i ritonavira u krvi.
At maternal doses producing systemic exposure levels similar to or below those at the recommended clinical dose, tipranavir did not produce teratogenic effects.
Pri dozama koje u majke rezultiraju sistemskom izloženošću koja je slična ili niža od one koja se postiže u ljudi preporučenom kliničkom dozom, tipranavir nije imao teratogene učinke.
Based on similarities in the elimination between pravastatin and rosuvastatin, TPV/r could increase the plasma levels of pravastatin.
Temeljem sličnosti eliminacije pravastatina i rosuvastatina, TPV/r može povisiti vrijednosti pravastatina u plazmi.
Before giving Aptivus you should check that the oral solution is clear.
Prije davanja Aptivusa potrebno je provjeriti da li je oralna otopina bistra.
Aptivus oral solution is available for children between 2 and 12 years of age (please refer to the respective SmPC for further details).
Za djecu između 2 i 12 godina starosti dostupna je Aptivus oralna otopina (molimo, referirati na relevantni Sažetak opisa svojstava lijeka za dodatne detalje).
Close clinical and biological (INR measurement) monitoring is recommended when warfarin and tipranavir are combined.
Preporučuje se pomno kliničko i biološko (INR mjerenje) praćenje kada se kombiniraju varfarin i tipranavir.
14-OH-clarithromycin Cmax ↓ 97% 14-OH-clarithromycin AUC ↓ 97% 14-OH-clarithromycin Cmin ↓ 95%
14-OH-klaritromicin Cmax ↓ 97% 14-OH-klaritromicin AUC ↓ 97% 14-OH-klaritromicin Cmin ↓ 95%
- jaundice (yellowing of the skin or the eyeballs)
- žutica (žutilo kože ili bjeloočnica)
Greater than 10-fold resistance to tipranavir is uncommon (< 2.5% of tested isolates) in viruses obtained from highly treatment experienced patients who have received multiple peptidic protease inhibitors.
Desetorostruka ili veća otpornost na tipranavir je manje česta (< 2,5% testiranih izolata) u izolatima bolesnika s opsežnim prethodnim liječenjem koji su primali višestruke peptidne inhibitore proteaze.
25-O-desacetylrifabutin AUC ↑ 21 fold
25-O-dezacetilrifabutin AUC ↑ 21 puta
Patients should be advised of the need to take Aptivus and ritonavir every day as prescribed.
Bolesnike je potrebno savjetovati da se Aptivus i ritonavir moraju svakodnevno primjenjivati prema propisanoj liječničkoj uputi.
The maximum volume which can be withdrawn at one time is 5 ml (equivalent to 500 mg tipranavir), which is the maximum single dose for a child with BSA > 1.33 m
Maksimalni volumen koji se može izvući u jednom trenutku je 5 ml (ekvivalentno 500 mg tipranavira), što je maksimalna pojedinačna doza za dijete s površinom tijela > 1,33 m
A correlation between the tipranavir mutation score and response to tipranavir with ritonavir therapy at week 48 has been established.
Utvrđena je povezanost između “mutacijskog skora“ tipranavira i reakcije na terapiju tipranavira s ritonavirom nakon 48. tjedna.
Patients using oestrogens as hormone replacement therapy should be clinically monitored for signs of oestrogen deficiency.
Bolesnice koje rabe estrogene kao nadomjesnu hormonsku terapiju moraju se klinički pratiti radi znakova deficijencije estrogena.
The most serious adverse reactions include hepatic impairment and liver toxicity.
Najteže nuspojave uključuju oštećenje jetre i toksičnost za jetru.
Your child can still pass on HIV when taking this medicine, although the risk is lowered by effective antiretroviral therapy.
HIV virus Vaše dijete može prenijeti čak i dok uzima ovaj lijek, iako je tada rizik od prijenosa manji zbog učinkovite antiretrovirusne terapije.
The metabolism of tipranavir in the presence of low dose ritonavir is minimal.
Metabolizam tipranavira u prisustvu niske doze ritonavira je minimalan.
Multivariate analyses showed that baseline ALAT or ASAT above DAIDS Grade 1 and co-infection with hepatitis B or C were risk factors for these elevations.
Multivarijatna analiza pokazala je da početna vrijednost ALT ili AST iznad DAIDS stupnja 1 i koinfekcija hepatitisom B ili C povećavaju rizik AST/ALT povišenja.
As a result of CYP3A4 inhibition and CYP2C19 induction by tipranavir/r, lansoprazole and pantoprazole plasma concentrations are difficult to predict.
Kao rezultat inhibicije CYP3A4 i indukcije CYP2C19 putem tipranavira/r, teško je predvidjeti koncentracije lanzoprazola i pantoprazola u plazmi.
Your child's doctor may have to increase or decrease the dose of other medicines which they take together with Aptivus.
Djetetov liječnik će možda morati povisiti ili sniziti dozu drugih lijekova koje Vaše dijete uzima zajedno s Aptivusom.
Phenobarbital and phenytoin induce CYP3A4.
Fenobarbital i fenitoin induciraju CYP3A4.
Aptivus/ritonavir dose (375 mg/m2 Aptivus + 150 mg/m2 ritonavir)
Aptivus/ritonavir doza (375 mg/m2 Aptivusa + 150 mg/m2 ritonavira)
Very common: may affect more than 1 in 10 people - Diarrhoea - Nausea (upset stomach)
Vrlo često: mogu se javiti u više od 1 na 10 osoba - proljev - mučnina
If observed, crystals are typically seen as a paper-thin layer on the bottom when the bottle is stored upright.
Kristali se tipično vide kao tanak sloj poput lista papira na dnu u izokrenutom položaju boce.
Psychiatric disorders uncommon insomnia, sleep disorder
Pshijatrijski poremećaji manje često nesanica, poremećaji spavanja
You should check with your child's doctor if they do wish to continue taking oral contraceptives or HRT.
Potrebno je provjeriti s djetetovim liječnikom ako Vaše dijete želi nastaviti uzimati oralne kontraceptive ili HNT.
A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4 (e.g. beclomethasone).
Potrebno je razmotriti ili sniženje doze glukokortikoida uz pomno praćenje lokalnih i sistemskih učinaka ili prijelaz na glukokortikoid koji nije supstrat CYP3A4 (npr. beklometazon).
If your child suffers increased bleeding you should see your child's doctor immediately.
Ako Vaše dijete ima pojačano krvarenje, potrebno je odmah se javiti djetetovom liječniku.
Remove the syringe cap covering the tip of the oral syringe (the cap will not be attached if this is the first time the oral syringe has been used) and insert the oral syringe into the adapter located in the neck of the bottle.
Uklonite kapicu sa štrcaljke koja pokriva vrh oralne štrcaljke (kapica neće biti biti pričvršćena ako je to prvi puta da se oralna štrcaljka koristi) te umetnite oralnu štrcaljku u nastavak smješten na vratu boce.
The mechanisms and potential mechanisms contributing to the interaction profile of tipranavir are described (see section 4.5).
Mehanizmi i potencijalni mehanizmi interakcija tipranavira opisani su u dijelu 4.5.
Rash:
Osip:
Particular caution should be used when prescribing the phosphodiesterase (PDE5) inhibitors sildenafil or vardenafil in patients receiving Aptivus, coadministered with low dose ritonavir.
Potreban je osobit oprez u propisivanju inhibitora fosfodiesteraze (PDE5), sildenafila, ili vardenafila za bolesnike koji primaju Aptivus s niskom dozom ritonavira.
Do not give Aptivus - if your child is allergic to tipranavir or any of the other ingredients of this medicine (listed in section 6) - if your child has moderate to severe liver problems.
Nemojte uzimati Aptivus - ako ste alergični na tipranavir ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.). - ako imate umjerene do teške probleme s jetrom.
It is recommended to prescribe tadalafil after at least 7 days of Aptivus with ritonavir dosing.
Preporučuje se da primjena tadalafila započne nakon najmanje 7 dana liječenja Aptivusom uz nisku dozu ritonavira.
Co-administration of tipranavir and low dose ritonavir with PDE5 inhibitors is expected to substantially increase PDE5 concentrations and may result in an increase in PDE5 inhibitorassociated adverse events including hypotension, visual changes and priapism.
Očekuje se da istodobna primjena tipranavira i niske doze ritonavira s PDE5 inhibitorima znatno povećava PDE5 koncentracije te može rezultirati povećanjem nuspojava povezanih s PDE5 inhibitorima, uključujući hipotenziju, promjenu vida i prijapizam.
If you suffer increased bleeding you should see your doctor immediately.
Ako imate pojačano krvarenje, potrebno je odmah se javiti liječniku.
Metabolic profile of tipranavir
Metabolički profil tipranavira
These tests will have confirmed that the HIV in your blood is resistant to most other protease inhibitors.
Ovi testovi će potvrditi da li je HIV u Vašoj krvi otporan na većinu drugih inhibitora proteaze.
Tipranavir resistant viruses which emerge in vitro from wild-type HIV-1 show decreased susceptibility to the protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir and ritonavir but remain sensitive to saquinavir.
Virusi rezistentni na tipranavir, koji nastaju in vitro iz divljeg tipa HIV-1, pokazuju smanjenu osjetljivost na inhibitore proteaze, amprenavir, atazanavir, indinavir, lopinavir, nelfinavir i ritonavir, ali ostaju osjetljivi na sakvinavir.
This indication is based on the results of two phase III studies, performed in highly pre-treated adult patients (median number of 12 prior antiretroviral agents) with virus resistant to protease inhibitors and of one phase II study investigating pharmacokinetics, safety and efficacy of Aptivus in mostly treatment-experienced adolescent patients aged 12 to 18 years.
Ova indikacija se zasniva na rezultatima dvaju ispitivanja faze III provodenima na odraslim bolesnicima koji su prethodno bili u značajnoj mjeri liječeni (medijan od 12 prethodnih antiretrovirusnih lijekova) s virusom rezistentnim na inhibitore proteaze, kao i na rezultatima jednog ispitivanja faze II koje je ispitivalo farmakokinetiku, sigurnost i djelotvornost Aptivusa na adolescentima u dobi 12 do 18 godina starosti koji su većinom već imali iskustvo liječenja.
Mild to moderate rash, including: - hives - rash with flat or raised small red spots - sensitivity to the sun have been reported in approximately 1 in 10 patients receiving Aptivus.
Blagi do umjereni osip, uključujući: - koprivnjaču - osip s ravnim ili izbočenim malih crvenim mrljama - osjetljivost na sunce je prijavljen kod oko 1 od 10 bolesnika koji su dobivali Aptivus.
You must take Aptivus together with ritonavir.
Morate uzimati Aptivus zajedno s ritonavirom.
Antipsychotics Pimozide
Antipsihotici Pimozid
In vitro studies show that tipranavir is a substrate and also an inhibitor of P-gp.
In vitro ispitivanja pokazuju da je tipranavir supstrat te također inhibitor P-gp-a.
Your child's doctor will carefully consider whether to treat them with combinations of Aptivus and protease inhibitors.
Djetetov liječnik će pažljivo razmotriti da li je Vašem djetetu potrebno liječenje kombinacijama Aptivusa i inhibitora proteaze.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING FOLDING BOX/OUTER PACKAGING
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU PREKLOPNA KUTIJA/VANJSKO PAKIRANJE
After four weeks of Aptivus 500 mg with 200 mg ritonavir (twice daily) the median plasma trough concentration of tipranavir was 43.9 µM for females and 31.1 µM for males.
Nakon četiri tjedna Aptivusa 500 mg s 200 mg ritonavira (dvaput dnevno), prosječne minimalne koncentracije tipranavira u plazmi bile su 43,9 µM u žena i 31,1 µM u muškaraca.
For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines.
Za praćenje lipida i glukoze u krvi upućuje se na utvrđene smjernice za liječenje HIV-a.
Close monitoring for signs of rilpivirine toxicity and possibly also dose adjustment of rilpivirine is recommended when coadministered with Aptivus/ritonavir.
Preporučuje se pažljivo praćenje znakova toksičnosti rilpivirina kao i mogućnost prilagodbe doze rilpivirina kod istodobne primjene s Aptivusom/ritonavirom.
PP * Composite endpoint defined as patients with a confirmed 1 log RNA drop from baseline and without evidence of treatment failure ** Comparator PI/RTV: LPV/r 400 mg/100 mg twice daily (n=358), IDV/r 800 mg/100 mg twice daily (n=23), SQV/r 1000 mg/100 mg twice daily or 800 mg/200 mg twice daily (n=162), APV/r 600 mg/100 mg twice daily (n=194)
* Kompozitni ishod: bolesnici s potvrđenim 1log RNA padom u odnosu na početnu vrijednost bez dokaza o neuspjehu liječenja ** Kontrolni PI/RTV: LPV/r 400 mg/100 mg dvaput dnevno (n=358), IDV/r 800 mg/100 mg dvaput dnevno (n=23), SQV/r 1000 mg/100 mg dvaput dnevno ili 800 mg/200 mg dvaput dnevno (n=162), APV/r 600 mg/100 mg dvaput dnevno (n=194)
Volume ritonavir (ml)
Volumen ritonavira (ml)
If your child takes aluminium- and magnesium-based antacid (used to treat dyspepsia/ gastrooesophageal reflux), the time interval between Aptivus and antacid should be at least two hours.
Ako Vaše dijete uzima antacide na bazi aluminija i magnezija (primjenjuju se u liječenju dispepsije/gastroezofagealnog refluksa), vremenski razmak između Aptivusa i antacida mora biti najmanje dva sata.
Co-administration of tipranavir and vitamin E has not been studied in dogs.
Istodobna primjena tipranavira i vitamina E nije ispitivana na psima.
Other HMG-CoA reductase inhibitors should be considered such as pravastatin, fluvastatin or rosuvastatin (See also section 4.4 and rosuvastatin and pravastatin recommendations).
Potrebno je razmotriti druge inhibitore HMGCoA reduktaze, kao što su pravastatin, fluvastatin, ili rosuvastatin (također vidjeti dio 4.4 te preporuke za rosuvastatin i pravastatin).
The clinical relevance of this reduction has not been established, but may decrease the efficacy of abacavir.
Klinički značaj ovog smanjenja nije utvrđen, ali može smanjiti djelotvornost abakavira.
Human experience with tipranavir overdose is very limited.
Iskustvo s predoziranjem tipranavirom u ljudi je vrlo ograničeno.
These have generally occurred in patients with advanced HIV disease taking multiple concomitant medicinal products.
Ti su događaji zabilježeni u bolesnika s uznapredovalom HIV bolešću, koji su istodobno uzimali veći broj lijekova.
In use storage: 60 days, after first opening of the bottle.
Čuvanje tijekom primjene: 60 dana nakon prvog otvaranja boce.
How to take Aptivus
Kako uzimati Aptivus
Your child's doctor will monitor their liver function by blood tests before and during Aptivus treatment.
Djetetov liječnik će pratiti funkciju jetre Vašeg djeteta putem testiranja krvi prije i tijekom liječenja Aptivusom.
HMG CoA reductase inhibitors Atorvastatin 10 mg QD Atorvastatin Cmax ↑ 8.6 fold Atorvastatin AUC ↑ 9.4 fold Atorvastatin Cmin ↑ 5.2 fold
Inhibitori HMG CoA reduktaze Atorvastatin 10 mg QD Atorvastatin Cmax ↑ 8,6 puta Atorvastatin AUC ↑ 9,4 puta Atorvastatin Cmin ↑ 5,2 puta
The safety and efficacy of Aptivus capsules in children aged 2 to 12 years has not been established.
Sigurnost i djelotvornost Aptivus kapsula u djece u dobi 2 do 12 godina nisu ustanovljene.
Intracranial haemorrhage (ICH) was only observed in post marketing experience (see section 4.4).
Intrakranijalno krvarenje je primijećeno jedino u postmarketinškom praćenju (vidjeti dio 4.4).
If you have any further questions about ritonavir or the other medicines you are prescribed, please ask your doctor or pharmacist.
Ako imate dodatnih pitanja o ritonaviru ili drugim lijekovima koji su Vam propisani, obratite se svom liječniku ili ljekarniku.
Other medicines with which Aptivus may interact include: - oral contraceptives/hormone replacement therapy (HRT): If you are taking the contraceptive pill to prevent pregnancy you should use an additional or different type of contraception (e.g. barrier contraception like condoms).
Ostali lijekovi s kojima Aptivus može imati interakcije uključuju: - oralne kontraceptive/hormonsku nadomjesnu terapiju (HNT): Ako uzimate kontracepcijske tablete za sprječavanje trudnoće, potrebno je primjenjivati dodatni ili drugačiji tip kontracepcije (npr. barijernu kontracepciju poput kondoma).
You should not use Aptivusif you have never received antiretroviral therapy or have other antiretroviral options available.
Ne smijete primjenjivati Aptivus ako nikada niste primali antiretrovirusnu terapiju ili su vam dostupne druge opcije antiretrovirusnog liječenja.
All patients had received at least two PI-based antiretroviral regimens and were failing a PI-based regimen at the time of study entry.
Svi su bolesnici prethodno dobivali najmanje dva antiretrovirusna režima na bazi IP-a, a u fazi uključenja u studiju pokazivali su izostanak terapijskog odgovora.
- didanosine: If you are taking didanosine enteric coated tablets, you should take them at least two hours before or after Aptivus.
- didanozin: ako uzimate želučanootporne tablete didanozina, potrebno je primjenjivati ih najmanje dva sata prije ili nakon Aptivusa.
INFORMATION IN BRAILLE Aptivus 100 mg/ml
16. PODACI NA BRAILLEOVOM PISMU Aptivus 100 mg/ml
The net effect will vary depending on the relative affinity of the co-administered substance for CYP3A and P-gp, and the extent of intestinal first-pass metabolism/efflux.
Neto učinak će varirati, ovisno o relativnom afinitetu istodobno primjenjivane tvari za CYP3A i P-gp, te opsegu intestinalnog metabolizma/efluksa.
Other medicines with which Aptivus may interact include: - oral contraceptives/hormone replacement therapy (HRT): If your child is taking the contraceptive pill to prevent pregnancy they should use an additional or different type of contraception (e.g. barrier contraception like condoms).
Ostali lijekovi s kojima Aptivus može imati interakcije uključuju: - oralne kontraceptive/ hormonsku nadomjesnu terapiju (HNT): Ako Vaše dijete uzima kontracepcijske pilule za sprječavanje trudnoće, potrebno je primjenjivati dodatni ili drugačiji tip kontracepcije (npr. barijernu kontracepciju poput kondoma).
In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
U bolesnika zaraženih HIV-om s teškom imunodeficijencijom u trenutku uspostave kombinirane antiretrovirusne terapije (CART) može se javiti upalna reakcija na asimptomatske ili rezidualne oportunističke patogene, te izazvati teška klinička stanja ili pogoršanje simptoma.
The human immunodeficiency virus (HIV-1) encodes an aspartyl protease that is essential for the cleavage and maturation of viral protein precursors.
Humani virus imunodeficijencije (HIV-1) kodira aspartil proteazu koja je nužna za segmentaciju i sazrijevanje prekursora virusnih proteina.
If you notice any of these symptoms please inform your child's doctor.
Ako primijetite neki od ovih simptoma kod Vašeg djeteta, molimo, obavijestite liječnika Vašeg djeteta.
These belong to a class of HIV medicines called nucleoside reverse transcriptase inhibitors (NRTIs).
Pripadaju skupini HIV lijekova koji se nazivaju nukleozidni inhibitori reverzne transkriptaze (NRTI).
When coadministered with ritonavir at the recommended dosage (see section 4.2) there is a net inhibition of P450 CYP3A.
Kada se primjenjuje istodobno s ritonavirom u preporučenim dozama (vidjeti dio 4.2), neto učinak jest inhibicija CYP3A.
Before starting treatment, your doctor will have taken blood samples to test the resistance of your HIV.
Prije početka liječenja, liječnik će uputiti uzorke Vaše krvi na testiranje otpornosti Vašeg HIV-a.
The ritonavir-boosted PI was chosen from among saquinavir, amprenavir, indinavir or lopinavir/ritonavir.
IP s dodatnim ritonavirom odabran je među sakvinavirom, amprenavirom, indinavirom, ili lopinavir/ritonavirom.
It is difficult to predict the net effect of Aptivus co-administered with low dose ritonavir on oral bioavailability and plasma concentrations of agents that are dual substrates of CYP3A and P-gp.
Teško je predvidjeti neto učinak Aptivusa s niskom dozom ritonavira na oralnu bioraspoloživost i koncentracije lijekova u plazmi koji su supstrati i CYP3A i P-gp-a.
Co-administration of valaciclovir, tipranavir and low dose ritonavir was not associated with clinically relevant pharmacokinetic effects.
Istodobna primjena valaciklovira, i tipranavira s niskom dozom ritonavira nije bila povezana s klinički značajnim farmakokinetičkim učincima.
For patients with renal impairment dose reduction of clarithromycin should be considered (see clarithromycin and ritonavir product information).
Za bolesnike s oštećenjem bubrega potrebno je razmotriti sniženje doze klaritromicina (vidjeti Sažetak opisa svojstva lijeka za ritonavir i klaritromicin).
Your child must NOT stop taking Aptivus unless your child's doctor instructs to do so.
Neka Vaše dijete NE prekida primjenu Aptivusa, osim ako Vas tako ne uputi djetetov liječnik.
The effective mean elimination half-life of tipranavir with ritonavir in healthy volunteers (n = 67) and HIV-infected adult patients (n = 120) was approximately 4.8 and 6.0 hours, respectively, at steady state following a dose of 500 mg/200 mg twice daily with a light meal.
Prosječni poluvijek eliminacije tipranavira s ritonavirom u zdravih dobrovoljaca (n = 67) i HIV-zaraženih odraslih bolesnika (n = 120) bio je oko 4,8 odnosno oko 6,0 sati, u stanju ravnoteže, nakon doze od 500 mg/200 mg dvaput dnevno, uz lagani obrok.
Rash accompanied by joint pain or stiffness, throat tightness, or generalized pruritus has been reported in both men and women receiving Aptivus co-administered with low dose ritonavir.
Osip popraćen bolovima ili ukočenošću zglobova, zatezanjem u grlu, ili generaliziranim pruritusom prijavljen je i u muškaraca i u žena koji su dobivali Aptivus s niskom dozom ritonavira.